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 ．Adverse reactions due to Futraful administration were subjectively observed in 9 of 75 cases （12％） ：
4 cases with skin eruption， 2 cases with anorexia， and 3 cases with gastrointestinal disorders．
   Laboratory examination of 35 cases， after one－year administration of Futraful， shewed the ab－
norrnal findings in 9 cases （23．7％）： 3 cases with decreased blood cell count， 3 cases with elevated
GO’1’ and GPT，’ and 3 cases with elevated alkaline phosphatase level．
   A problem in bladder cancer after a conservative is the frequent local recurrence of the tumor．
Intravesical administration of MMC or Thio－TEPA and／or oral administration of SLA have been
recognized as a successful prophylactic rneasure，
   In this paper， the prophylactic effect of Futraful administration was tested between 75 patients
and 110 controls with transitional cell carcinoma． Futraful was orally administered 600～800皿9
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半 a day for one to two years to the patients operated by either TUR （TUC）， simple resection， or partial
  cystectomy．
   The rate of recurrence was significantly lower for the postoperative period of O N 10 months and
  lower， though insignificantly， for that of 11一一24 months in the patients operated for the first time， as
  compared to thqt in the controls； the rate of postoperative recurrence after 12 months being 15．5％
  in the patients treated by Futrafu1’ and 25．5％ in the controis．
    In the recurrent cases， however， administration of Futrafu1 effectively reduced the recurrence
  only for the postoperative period of O一一’6 months； the rate of recurrence being higher thereafter in





































































   Table 2．症例背景因子
453
初回 対照 合計 再発 対照 合計
～50 4 25 29 2 25 27
年
51～60 11 28 392X 謹 4 28 32X2罵
61～70 15 28 43 a94 7 28 353．06A7 71～ 11 29 40 8 29 37
合計 41110151 21 1’P0 13正
男 34 89123 2X ＝ 19 89 108X2＝性
女 7 2！ 28 α080 2 21 23 L12別
合計 41 110151 21 110131
単 発 30 85115X2＝ 13 8598X2＝
数 多 発 11 25 36α28 8 25 33a21
合計 411！o 15！ 21 110 ．13、1
TUR27 78105 16 78 94手
膀 切 4 15 19X2＝ 1 15 正6 2X ＝
術 部 切 正0 17 27 1．80 4 17 21 t35
合計 41 1正0 151 21 110 131
．  
1 7 13 20 2 13 ！5姫3 2 20 45 65 2X 隔 8 45 53X2冨
倉 3 9 16 25 028 5 16 21 α97
合計 36 74110 15 マ4 89
ω O 1 11 12 1 11 12
鑓 A 10 29 39 2X ロ 8 29 37X2竃
鵯
B以上 7 11 18 350 9 11 20   ※ao5
合計 18 51 69 18 51 69
 ユX   f＝1  3．84
（O．05） f＝2   5．99
    f＝3  7．81
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 血球減少       3
 GO’「， GPT上昇  3
 Al－P上昇     3















 GOT． GPT上昇例のeg 1例は，68歳男子で投与開
始後5ヵ月目に， GOT 48単位， GPT 82単位の上
昇がみられたが，投与を中止することなく正常化し
た．第2例は73歳の女子でFT投与開始後5ヵ月で，
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